Gmpj. Costongs et Bm. Bas, THE FIRST FULLY AUTOMATED ALLERGY ANALYZER UNICAP - COMPARISON WITH IMMULITE FOR ALLERGY PANEL TESTING, European journal of clinical chemistry and clinical biochemistry, 35(11), 1997, pp. 885-888
Automated immunoassay systems should be convenient to handle, flexible
and give reliable results. To investigate the extent to which the Uni
CAP System met the above requirements, compared with the IMMULITE Syst
em, we compared the Phadiatop (UniCAP) and AlaTOP (IMMULITE) results o
f 110 patients with positive clinical diagnoses for inhalant allergy.
In addition, we compared food screening test results of 103 patients w
ith a clinical positive diagnosis for food, and 110 test results of co
ntrols with negative diagnosis for allergy. Phadiatop had a sensitivit
y of 96% and a specificity of 92%. AlaTOP had a sensitivity of 86% and
a specificity of 94%. For food screening the results were: 75% sensit
ivity and 82% specificity for fx5 (UniCAP) and 63% sensitivity and 71%
specificity for fp5 (IMMULITE). Furthermore, those samples for which
the test results which were not in concordance with the clinical diagn
osis were rested with the follow-up panel of the different screening t
ests. For the AlaTOP follow-up we had to use the DPC microplate System
(Milenia), because single allergen testing is not yet possible on the
IMMULITE System. With regard to sensitivity, the UniCAP specific inha
lant allergen tests and the original Phadiatop results showed closer a
greement with each other than did the Milenia specific allergen result
s with the AlaTOP. The specificity of the single inhalant allergen tes
ts was the same for both systems. For food allergy testing the UniCAP
System shows closer agreement between the screening and the follow-up
results than does the IMMULITE. The hands on time for loading 44 sampl
es was practically the same for both systems, but for the follow-up te
sts the Milenia System is used next to the IMMULITE. Therefore from a
logistical point of view the UniCAP System is more convenient. From th
ese results we conclude that both logistically and clinically UniCAP s
eems to meet our requirements better than the IMMULITE.